Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study.
[PURPOSE] The aim of this multicenter retrospective study was to evaluate the impact of statin use on clinical outcomes in patients with unresectable pancreatic cancer (PC) receiving gemcitabine plus
APA
Saito K, Nakai Y, et al. (2025). Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study.. Pancreas, 54(2), e107-e113. https://doi.org/10.1097/MPA.0000000000002411
MLA
Saito K, et al.. "Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study.." Pancreas, vol. 54, no. 2, 2025, pp. e107-e113.
PMID
39928888
Abstract
[PURPOSE] The aim of this multicenter retrospective study was to evaluate the impact of statin use on clinical outcomes in patients with unresectable pancreatic cancer (PC) receiving gemcitabine plus nab-paclitaxel (GnP) in a large Japanese cohort.
[MATERIALS AND METHODS] We retrospectively reviewed the medical records including data on the use of concomitant medications in patients with unresectable PC receiving GnP between January 2015 and January 2019 at 10 hospitals. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were evaluated.
[RESULTS] A total of 1682 patients were included in the analysis; of which 322 patients (19%) received statins and 1360 (81%) did not receive statin. The median PFS and OS were 7.5 versus 7.3 months (P = 0.87) and 15.1 versus 14.4 months (P = 0.48) in cases with and without statin use. The use of statin was not associated with PFS (hazard ratio, 1.01; 95% confidence interval, 0.85-1.18, P = 0.93) or OS (hazard ratio, 1.05; 95% confidence interval, 0.91-1.21, P = 0.47) in the multivariable analyses. PFS and OS did not significantly differ by liposolubility of statins, either.
[CONCLUSIONS] Stain use was not associated with PFS or OS in patients with unresectable PC receiving GnP.
[MATERIALS AND METHODS] We retrospectively reviewed the medical records including data on the use of concomitant medications in patients with unresectable PC receiving GnP between January 2015 and January 2019 at 10 hospitals. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were evaluated.
[RESULTS] A total of 1682 patients were included in the analysis; of which 322 patients (19%) received statins and 1360 (81%) did not receive statin. The median PFS and OS were 7.5 versus 7.3 months (P = 0.87) and 15.1 versus 14.4 months (P = 0.48) in cases with and without statin use. The use of statin was not associated with PFS (hazard ratio, 1.01; 95% confidence interval, 0.85-1.18, P = 0.93) or OS (hazard ratio, 1.05; 95% confidence interval, 0.91-1.21, P = 0.47) in the multivariable analyses. PFS and OS did not significantly differ by liposolubility of statins, either.
[CONCLUSIONS] Stain use was not associated with PFS or OS in patients with unresectable PC receiving GnP.
MeSH Terms
Humans; Retrospective Studies; Pancreatic Neoplasms; Male; Female; Paclitaxel; Gemcitabine; Aged; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Albumins; Deoxycytidine; Middle Aged; Antineoplastic Combined Chemotherapy Protocols; Aged, 80 and over; Japan; Progression-Free Survival; Adult
같은 제1저자의 인용 많은 논문 (3)
- Comparison of preoperative neutrophil-percentage-to-albumin ratio, systemic immune-inflammatory index, and neutrophil-to-lymphocyte ratio for predicting postoperative delirium in patients undergoing head and neck free-flap reconstruction surgery: a retrospective observational study.
- Interleukin-1 receptor type 1 in pancreatic cancer progression and metastasis: a review.
- Long-term effects of combined botulinum toxin treatment and rehabilitation on upper limb muscle spasms: a case report.